UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 18, 2007
GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 0-19635 (Commission File Number) |
33-0326866 (IRS Employer Identification No.) |
|
| 200 Connell Drive Berkeley Heights, NJ (Address of Principal Executive Offices) |
07922 (Zip Code) |
(908) 286-9800
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On October 18, 2007, Genta Incorporated, (the Company), announced that new clinical and preclinical data on Genasense® (oblimersen sodium) Injection, its lead anticancer compound, will be presented at the “Molecular Targets and Therapeutics” conference that will take place from October 22-26, 2007 in San Francisco, CA. The “Targets” meeting is jointly sponsored by the U.S. National Cancer Institute (NCI), the American Association for Cancer Research (AACR), and the European Organization for the Research and Treatment of Cancer (EORTC).
Item 9.01 Financial Statements and Exhibits.
|
(d) Exhibits. |
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release of the Company dated October 18, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
GENTA INCORPORATED | ||
|
|
|
|
| ||
|
Date: |
October 18, 2007 |
|
By: |
| |
|
|
|
|
|
Name: |
Richard J. Moran |
|
|
|
|
|
Title: |
Senior Vice President, Chief Financial Officer and Corporate Secretary |
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
Sequentially |
|
99.1 |
|
Press Release of the Company dated October 18, 2007 |
|
|